Novo says high-dose Wegovy can cause 28% weight loss

Pharmaphorum

Novo Nordisk has built the case for migration to its 'triple-dose' version of injectable GLP-1 Wegovy with new weight-loss and body composition data.

pharminent May 12, 2026 (Last updated: May 12, 2026)

Pharmaphorum

Novo Nordisk has built the case for migration to its ‘triple-dose’ version of injectable GLP-1 Wegovy with new weight-loss and body composition data.

Related Stories